logo

(RBOT)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for RBOT

11/13/2026: RBOT (1-star) is currently NOT-A-BUY. Pass it for now.

Vicarious Surgical Inc. is a speculative, pre-commercial medical robotics company focused on developing a single-incision surgical platform. Its main strength lies in its innovative, human-like robotic instrument technology, which aims to improve upon traditional multi-port surgical systems. The primary investment story centers on the potential for FDA clearance and subsequent commercialization in high-volume abdominal surgeries. However, the company faces significant execution, regulatory, and competitive risks from established leaders like Intuitive Surgical. This stock is best suited for high-risk tolerance growth investors who should closely monitor updates regarding clinical trial progress, cash burn rates, and potential regulatory milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers high growth potential but remains speculative due to the lack of a commercialized product.
Momentum investorWeak fitThe stock has lacked consistent upward momentum, making it less attractive for trend-following strategies.
Value investorWeak fitThe company lacks current earnings or traditional valuation metrics, failing typical value screening criteria.
Dividend investorWeak fitThe company does not pay dividends and is not expected to do so in the foreseeable future.
Low-risk investorWeak fitThe high volatility and binary nature of clinical/regulatory success make this unsuitable for risk-averse portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock's pre-commercial status often leads to significant price swings based on news cycles.
Valuation riskHighValuations are highly sensitive to long-term assumptions about product adoption that remain unproven.
Competition risk (Robotic Surgery Market)HighDominant competitors have established deep moats and extensive hospital relationships.
Business qualityMediumThe core technology is innovative, but the lack of revenue limits the current franchise quality.
Dividend incomeLow / noneThis is a growth-stage capital-intensive company with no capacity for payouts.
Execution riskHighMoving from R&D to FDA clearance and hospital sales is a notoriously difficult transition.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 0.02M USD
Price to earnings Ratio -
1Y Target Price 5
Price to earnings Ratio -
1Y Target Price 5
Volume (30-day avg) - shares
Beta 2.38
52 Weeks Range 0.00 - 3.66
Updated Date 11/14/2026
52 Weeks Range 0.00 - 3.66
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -6.63

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 0%
Avg. Invested days 0
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 0.0
Stock Returns Performance Upturn Returns Performance icon 0.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
RBOT receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft quantitative characteristics, and soft analyst coverage.

Company Fundamentals

★★★★★
RBOT has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, solid earnings growth (+20.6%) is partially offset by soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
RBOT's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is RBOT's strongest growth driver at +20.6% FY2025 versus FY2024 (solid, 4 stars). By comparison, while revenue growth (+0.0%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 14.9% and approximately 64.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 14.84% supports management-shareholder alignment.

Top 5 Institutional Investors

K5 Global Advisor LLC 0.01%
SignatureFD, LLC 0.00%
Sound Income Strategies 0.00%
Hughes Financial Services, LLC 0.00%
Aspex Management (HK) Ltd 0.00%

Unit Economics (Per $1K Revenue)

★★★★★
RBOT generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
RBOT has a liquid profile. Soft valuation is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Robotic Surgical SystemsFuture sales of the Vicarious Surgical robotic system, service contracts, and disposable instrument revenue.The company expects to make money by eventually selling robots and the recurring supplies used for each surgery.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 3.72M
Price to Sales(TTM) -
Enterprise Value 3.72M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 24.74
Shares Outstanding 6.48M
Shares Floating 4.16M
Shares Outstanding 6.48M
Shares Floating 4.16M
Percent Insiders 14.84
Percent Institutions 14.94

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.